Atıf İçin Kopyala
Shitara K., ÖZGÜROĞLU M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., ...Daha Fazla
ANNALS OF ONCOLOGY, cilt.32, sa.9, ss.1127-1136, 2021 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
32
Sayı:
9
-
Basım Tarihi:
2021
-
Doi Numarası:
10.1016/j.annonc.2021.05.803
-
Dergi Adı:
ANNALS OF ONCOLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
-
Sayfa Sayıları:
ss.1127-1136
-
Anahtar Kelimeler:
pembrolizumab, chemotherapy, tumor mutational burden, gastroesophageal adenocarcinoma, gastric cancer, TUMOR MUTATIONAL BURDEN, CTLA-4 BLOCKADE, PD-1 BLOCKADE, BENEFIT, CHEMO
-
İstanbul Üniversitesi Adresli:
Hayır
Özet
Background: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) >= 1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status.